American Century Companies’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

American Century Companies’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-101,636	Closed	-$10.8M	–	2865
2023 Q1	$10.8M	Buy	101,636 +71,093	+233%	+$8.18M	0.01%	990
2022 Q4	$3.36M	Buy	+30,543	New	+$1.98M	﹤0.01%	1376

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

American Century Companies's RXDX Position: Q2 2023 in Review

American Century Companies sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 101,636 shares — an estimated $10.8M sold.

American Century Companies first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $10.8M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

American Century Companies reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
American Century Companies sold 101,636 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $10.8M.
American Century Companies first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
American Century Companies's Prometheus Biosciences, Inc. Common Stock position peaked at $10.8M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on American Century Companies's 13F filing for Q2 2023, filed 14 Aug 2023.